Analyst Price Target is $26.56
▲ +159.46% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $26.56, with a high forecast of $50.00 and a low forecast of $8.00. The average price target represents a 159.46% upside from the last price of $10.24.
Current Consensus is
Moderate Buy
The current consensus among 9 contributing investment analysts is to moderate buy stock in Arcutis Biotherapeutics. This Moderate Buy consensus rating has held steady for over two years.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical formulation of ivarmacitinib designed to reach deeper into the skin in order to treat alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More